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Background: Patients with breast cancer (BC) show strong interest in complementary and alternative
medicine (CAM), particularly for adverse effects of adjuvant endocrine treatment d e.g., with letrozole.
Letrozole often induces myalgia/limb pain and arthralgia, with potential noncompliance and treatment
termination. This analysis investigated whether CAM before aromatase inhibitor (AI) therapy is associ-
ated with pain development and the intensity of AI-induced musculoskeletal syndrome (AIMSS) during
the first year of treatment.
Patients and methods: The multicenter phase IV PreFace study evaluated letrozole therapy in post-
menopausal, hormone receptorepositive patients with early BC. Patients were asked about CAM use
before, 6 months after, and 12 months after treatment started. They recorded pain every month for 1 year
in a diary including questions about pain and numeric pain rating scales. Data were analyzed for patients
who provided pain information for all time points.
Results: Of 1396 patients included, 901 (64.5%) had used CAM before AI treatment. Throughout the
observation period, patients with CAM before AI treatment had higher pain values, for both myalgia/limb
pain and arthralgia, than non-users. Pain increased significantly in both groups over time, with the
largest increase during the first 6 months. No significant difference of pain increase was noted regarding
CAM use.
Conclusions: CAM use does not prevent or improve the development of AIMSS. Pain intensity was
generally greater in the CAM group. Therefore, because of the risk of non-compliance and treatment
discontinuation due to the development of higher pain levels, special attention must be paid to patient
education and aftercare in these patients.
© 2020 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
According to current guidelines, postmenopausal women with
hormone receptorepositive early breast cancer (BC) should receive
adjuvant endocrine treatment d i.e., tamoxifen or an aromatase
inhibitor (AI)d in order to reduce the risk of recurrence [1,2]. Since
AI therapy is more effective in these patients [3e6], it is a standard
treatment in the adjuvant setting [7,8]. However, AIs are known to
induce musculoskeletal pain as one of the main side effects [9e13],
so that patients often become noncompliant [11] and discontinue
treatment [9,12e15]. Noncompliance and early cessation of treat-
ment in turn lead to a poorer prognosis [12,16]d emphasizing the
importance of maintaining patients’ compliance and persistence.
Several pharmacological and nonpharmacological methods
aimed at improving therapy adherence with AIs have been
analyzed [13,17e20]. Analgesics or a switch to another antihor-
mone therapy, for instance, significantly reduced pain [19,21,22].
Providing patients with additional information material does not
appear to affect compliance and persistence with anastrozole [23].
Although yoga has been reported to significantly improve muscu-
loskeletal symptoms in various trials [17,19,24,25], there are con-
tradictory results in relation to physical activity [18,19,26,27]; and
the same applies to acupuncture [19,20,28,29] and other comple-
mentary and alternative medicines (CAM) [19,30,31].
Patients are strongly interested in CAM [32,33] d particularly
those who are dissatisfied with the information provided regarding
their disease [33]. A cross-sectional study mainly including post-
menopausal patients with early breast cancer found that 69% of the
patients were physically active, 87% paid attention to nutrition, and
46% used CAM [34]. Almost 50% of postmenopausal BC patients
treated with an AI are interested in CAM [33]. An Australian study
investigating strategies for managing aromatase inhibitor muscu-
loskeletal syndrome (AIMSS), including CAM, noted only limited
effectiveness of CAM in patients who had AIMSS [13].
The aim of this analysis was therefore to investigate whether
using CAM before the start of AI treatment is associated with the
development of pain and with the severity of AIMSS during the first
12 months of adjuvant letrozole treatment, in postmenopausal
patients with hormone receptorepositive breast cancer.2. Patients and methods
2.1. Patients
The PreFace study is a multicenter, noninterventional and
observational phase IV study in which letrozole is being evaluated
in postmenopausal, hormone receptorepositive, AI-naïve early BC
patients (Clinical Trial Number: NCT01908556). Inclusion criteria
were: histologically confirmed hormone receptorepositive, non-
metastatic breast cancer, female patients aged 18 years, and
postmenopausal status. Patients who had received endocrine
treatment for breast cancer with an aromatase inhibitor in the past,
or who did not have an indication for letrozole, were excluded.
Between 2009 and 2010, 3481 postmenopausal patients were
enrolled at 220 sites in Germany. Patients were excluded in the
following hierarchical order: unknown documentation of the start
of treatment (103 patients excluded); lost to follow-up (77 patients
excluded); no return of the pain diary or no pain information at
baseline (875 patients excluded); incomplete diary with at least
one missing item of pain information during the follow-up (1012
patients excluded); and no information on CAM use (18 patients
excluded). A total of 1396 patients with complete datasets were
therefore finally included in the analysis (Fig. 1).
Patients received letrozole at 2.5 mg per day. Letrozole treat-
ment was continued for a maximum of 5 years or until recurrence
of BC. All of the patients provided written informed consent, and all
of the relevant ethics committees approved the study.
2.2. Data acquisition
Data on patient and tumor characteristics were documented in
electronic case report forms. The tumor characteristics noted
included stage and previous treatments. Patient information
included common epidemiological characteristics, comorbidities,
and concomitant medication. There were four prespecified study
visits after 6,12, 24, and 60months from the time of inclusion in the
trial. At the follow-up visits, the patients’ disease status was
assessed and they were asked about compliance and adverse
events. In addition, to assess musculoskeletal side effects during
Fig. 1. Patient recruitment algorithm. CAM, complementary and alternative medicine.
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numeric rating scales from 0 (no pain) to 10 (very strong pain) was
issued to each patient at the time of inclusion. Patients were asked
to document any symptoms at monthly intervals. For months 0, 6,
and 12 the diary also included questions regarding the use of CAM.
The patients were asked each time whether they were currently
using or had in the past used vitamins, high-dose vitamin C, food
supplements, mistletoe, enzymes, acupuncture, homeopathy, Chi-
nese herbs/tea, mushrooms, meditation, prayer, relaxation tech-
niques, yoga, t’ai chi, qigong, or bioresonance. Only the data at
month 0 d i.e. before the start of endocrine treatment d were
evaluated for the present analysis.
2.3. Statistical methods
Nonparametric methods were used, as the outcome data were
skewed with many zeros. Patients were divided into two groups:
one group consisting of patients who had used CAM before the start
of AI treatment and the other of patients who were not using CAM.
Statistical tests were performed for patients with complete
observations. Myalgia/limb pain and arthralgia were analyzed
separately. For each patient, the mean pain score over all assess-
ments (average of 12 values) was calculated. To analyze the influ-
ence of CAM on pain during AI treatment, the pain score before the
start of AI treatment was subtracted from the mean pain score for
all assessments. Both patient groups were then compared using the
Wilcoxon rank sum test.
To assess the course of pain, the pain values at month 1 and
month 6 were compared within each patient group, as well as the
pain values at month 6 and month 12, using Wilcoxon signed rank
tests. Significant test results indicated changes in pain during
therapy. If both tests within a group were significant, the difference
between the pain values at months 1 and 6 was compared with thedifference between months 6 and 12 using a Wilcoxon signed rank
test. A significant test result shows that the increase or decrease
changed during therapy. For each of the two time intervals (the first
and second 6-month periods), the difference in the CAM group was
compared with the difference in the non-CAM group to assess
whether the course of pain development differed between the
patient groups, given that both differences had been significant
using the Wilcoxon rank sum test.
Mean and median values are shown. Confidence intervals for
mean values were determined using 10,000 bootstrap samples.
Since the pain values were not symmetrically distributed, the mean
values should be interpreted cautiously together with median
values.
Pain development relative to CAM status before AI treatment
and after 6 months of treatment are shown for descriptive pur-
poses, rather than for hypothesis testing.
All of the tests were two-sided, and a p value < 0.05 was
regarded as statistically significant. Calculations were carried out
using the R system for statistical computing (version 3.0.1; R
Development Core Team, Vienna, Austria, 2013).
3. Results
3.1. Patients
The study population consisted of 1396 patients who completed
questionnaires about their pain levels at each of the observation
time points and also answered the questions about CAM use. Of
these, with a total of 901 patients (64.5%) themajority declared that
they had already used CAM before AI treatment start, while 495
patients (35.5%) were non-CAM users.
The patients’ average agewas 63.5 (standard deviation 7.4) years
in the non-CAM group and 62.6 (SD 7.1) years in the CAM group.
Their average body mass index (BMI) was 27.5 kg/m2 (SD 5.4) in the
CAM group and 26.8 kg/m2 (SD 4.9) in the non-CAM group. Among
the patients in the non-CAM group, 30.7% (n ¼ 141) were currently
receiving or had formerly received hormone replacement therapy
(HRT), in comparison with 39.9% (n ¼ 343) of those in the CAM
group. Most of the patients in both groups had a negative nodal
status (pN0) and a low tumor stage (pT1). The characteristics of the
patients and tumors are shown in Table 1. Additionally, there did
not appear to be any major differences between patients who did
not return the patient diary, those who returned it but provided
incomplete information about pain levels at the required time
points, and those who returned the diary with complete informa-
tion (Supplementary Table 1).
3.2. Myalgia/limb pain
The patient-reported outcomes for myalgia/limb pain during
course of treatment are shown in Fig. 2a and summarized in Table 2.
Patients who had used CAM before AI treatment had consistently
higher pain values than non-users throughout the observation
time. The average pain value across all observation time points
among the CAM users was 3.3 (95% CI, 3.6 to 3.4; median 3.2), while
in the non-CAM users it was 2.8 (95% CI, 2.6 to 3.0; median 2.7).
However, the pain values before AI treatment were also higher in
the CAM group than in the non-CAM group. The average increase
during AI treatment was 1.1 units (95% CI, 1.0 to 1.3) in the CAM
group and 1.0 units (95% CI, 0.8 to 1.2) in the non-CAM group
(Table 2). No differences in the increases between the two patient
groups were found (p ¼ 0.23, Fig. 2b).
Myalgia/limb pain values for selected time points are presented
in Table 3. In both patient groups myalgia/limb pain values
increased over 12 months. However, the strongest increase in both
Table 1
Characteristics of the patients and tumors.
Characteristic No use of CAM before
AI treatment (n¼ 495)
Use of CAM before AI
treatment (n ¼ 901)
Mean or n SD or % Mean or n SD or %
Age (year) 63.5 7.4 62.6 7.1
Body mass index (kg/m2) 27.5 5.4 26.8 4.9
Hormone replacement therapy
Never 319 69.3 517 60.1
Former 95 20.7 241 28.0
Current 46 10.0 102 11.9
Neoadjuvant chemotherapy
No 453 92.6 817 91.5
Yes 36 7.4 76 8.5
Adjuvant chemotherapy
No 337 69.5 574 64.4
Yes 148 30.5 317 35.6
Lymph-node status
pN0 348 70.7 640 71.7
pNþ 144 29.3 253 28.3
Tumor stage
pT0 8 1.6 6 0.7
pT1 323 65.7 587 65.7
pT2 138 28 271 30.3
pT3 18 3.7 25 2.8
pT4 5 1.0 5 0.6
Estrogen receptor
Negative 1 0.2 15 1.7
Positive 490 99.8 882 98.3
Progesterone receptor
Negative 68 13.8 120 13.4
Positive 424 86.2 778 86.6
Tumor grade
G1 106 21.5 160 17.9
G2 318 64.5 559 62.4
G3 69 14.0 177 19.8
AI, aromatase inhibitor; CAM, complementary and alternative medicine.
Means and standard deviation (SD) are shown for continuous characteristics, and
frequency and percentage for categorical characteristics.
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and 0.6 units, each p < 0.00001, Table 4). Afterwards, the increase
was weaker, but still significant, in the CAM group (mean increase
0.2 units, p < 0.001), while in the non-CAM group pain assessments
remained almost constant (mean increase 0.1 unit, p ¼ 0.15).Fig. 2. Myalgia/limb pain during the course of treatment. Solid curves show (a) mean pai
treatment. The corresponding 95% confidence intervals are indicated by the lines with long3.3. Arthralgia
The development of arthralgia was similar to that of myalgia/
limb pain. CAM users reported higher pain values than non-CAM
users at all time points. Pain values before therapy were also
higher among CAMusers (Fig. 3a and Table 2). Changes in painwere
similar in the two patient groups after taking into account
arthralgia assessments before the start of AI treatment (Fig. 3b and
Table 2). Pain values of arthralgia also increased in both patient
groups over 12 months. The increase in pain was significantly
greater in the first 6 months than afterwards in both groups (mean
increases 0.9 and 0.8 units, each p < 0.00001, Table 4). Between
months 6 and 12 it was also significant, but weaker (mean increase
of 0.2 units in non-CAMusers and 0.3 units in CAM users, p 0.01 and
p < 0.001, respectively, Table 4). There was no evidence of varyingly
strong pain increases between the two patient groups, either in the
first 6 months or in the second 6 months of the observation period
(Table 4).
3.4. Myalgia/limb pain and arthralgia in the course of therapy
relative to CAM status
In an exploratory analysis, the pain levels over timewere plotted
relative to CAM status before AI treatment and after 6 months
(Suppl. Fig. 1a and 1b). In general, patients who did not use CAM
before and in the first 6 months of AI treatment showed constantly
the lowest levels of pain compared to those who used CAM at some
point of time. Patients who did not use CAM before AI treatment,
but used it later on, did not experience a serious reduction in
myalgia/limb pain or arthralgia. Conversely, patients who first used
CAM and later stopped it due to reduced symptoms showed a
renewed increase in pain, both in myalgia/limb pain and arthralgia.
4. Discussion
This study shows that patients who were CAM users before AI
treatment had generally higher pain values d for myalgia/limb
pain as well as for arthralgia d than non-users throughout the
observation period. An increase in pain levels of myalgia/limb pain
and arthralgia was registered in both patient groups over time,n values and (b) mean pain value changes since the start of aromatase inhibitor (AI)
dashes. CAM, complementary and alternative medicine.
Table 2
Overall pain across all time points.
Outcome No use of CAM before AI treatment (n ¼ 495) Use of CAM before AI treatment (n ¼ 901)
Mean (95% CI) Median (IQR) Mean (95% CI) Median (IQR)
Myalgia/limb pain
Average throughout AI treatmenta 2.8 (2.6, 3.0) 2.7 (0.5, 4.5) 3.3 (3.1, 3.4) 3.2 (1.4, 4.9)
Before AI treatment 1.7 (1.5, 1.9) 0.0 (0.0, 3.0) 2.1 (2.0, 2.3) 1.0 (0.0, 4.0)
Differenceb 1.0 (0.8, 1.2) 0.8 (0.0, 2.2) 1.1 (1.0, 1.3) 0.8 (0.0, 2.6)
Arthralgia
Average throughout AI treatment 2.9 (2.7, 3.1) 3.0 (0.6, 4.9) 3.4 (3.3, 3.6) 3.4 (1.5, 5.2)
Before AI treatment 1.8 (1.6, 1.8) 0.0 (0.0, 3.0) 2.3 (2.1, 2.4) 2.0 (0.0, 4.0)
Difference 1.1 (1.0, 1.3) 0.8 (0.0, 2.3) 1.2 (1.0, 1.3) 1.0 (0.0, 2.3)
AI, aromatase inhibitor; CAM, complementary and alternative medicine; CI, confidence interval(s); IQR, interquartile range.
a The mean pain score over 12 pain assessments (one per month) was calculated for each patient. Patients with missing values were excluded.
b Difference between the mean pain assessments during AI treatment and the pain assessment before the start of AI treatment.
Table 3
Pain score at selected time points.
Myalgia/limb pain Arthralgia
No use of CAM before AI
treatment
Use of CAM before AI treatment No use of CAM before AI
treatment
Use of CAM before AI treatment
Mean (95% CI) Median (IQR) Mean (95% CI) Median (IQR) Mean (95% CI) Median (IQR) Mean (95% CI) Median (IQR)
Month 1 2.2 (2.0, 2.4) 1 (0, 4) 2.7 (2.5, 2.8) 3 (0, 4) 2.1 (1.9, 2.3) 1 (0, 4) 2.7 (2.6, 2.9) 3 (0, 4)
Month 6 2.8 (2.6, 3.1) 3 (0, 5) 3.3 (3.1, 3.5) 3 (1, 5) 3.0 (2.8, 3.2) 3 (0, 5) 3.5 (3.3, 3.7) 3 (1, 5)
Month 12 2.9 (2.7, 3.2) 3 (0, 5) 3.5 (3.3, 3.7) 3 (1, 6) 3.2 (3.0, 3.4) 3 (0, 5) 3.8 (3.6, 4.0) 4 (1, 6)
AI, aromatase inhibitor; CAM, complementary and alternative medicine; CI, confidence interval(s); IQR, interquartile range.
Table 4
Course of myalgia/limb pain and arthralgia during therapya.
Myalgia/limb pain
No use of CAM before AI treatment (n¼ 495) Use of CAM before AI treatment (n¼ 901)
Outcome Mean (95% CI) Median (IQR) p value Mean (95% CI) Median (IQR) p value p valueb
Difference, month 1 vs. month 6 0.7 (0.4, 0.9) 0 (0, 2) <0.00001 0.6 (0.5, 0.8) 0 (0, 2) <0.00001 0.98
Difference, month 6 vs. month 12 0.1 (0.1, 0.3) 0 (1, 1) 0.15 0.2 (0.1, 0.4) 0 (1, 1) <0.001 e
p valued ec 0.02
Arthralgia
No use of CAM before AI treatment (n¼ 495) Use of CAM before AI treatment (n¼ 901)
Outcome Mean (95% CI) Median (IQR) p value Mean (95% CI) Median (IQR) p value p valueb
Difference, month 1 vs. month 6 0.9 (0.7, 1.1) 0.0 (0.0, 2.0) <0.00001 0.8 (0.6, 0.9) 0 (0, 2) <0.00001 0.55
Difference, month 6 vs. month 12 0.2 (0.0, 0.4) 0.0 (0.5, 1.0) 0.01 0.3 (0.1, 0.4) 0 (1, 1) <0.001 0.38
p valued <0.001 <0.01
AI, aromatase inhibitor; CAM, complementary and alternative medicine; CI, confidence interval(s); IQR, interquartile range.
a Positive differences mean increasing pain during the course of therapy, negative differences indicate decreasing pain.
b A significant p value shows that pain changes varied between the two patient groups.
c No statistical testing was performed, as the prespecified conditions for testing were not fulfilled.
d A significant p value shows that the increase in pain became weaker or stronger over the course of time.
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weaker, but still significant in both groups, except for the non-CAM
users regarding myalgia/limb pain. CAM use did not appear to be
associated with different changes in pain increase over time.
However, a large proportion of the patients, at 64.5%, reported
ongoing CAM at the time of diagnosis of breast cancer and before
the start of AI treatment.
Few data are available concerning the association between CAM
use before the onset of AIMSS and the development of musculo-
skeletal pain afterwards, in order to support the treatment of
postmenopausal breast cancer patients who are receiving adjuvant
aromatase inhibitor therapy. To the best of our knowledge, the
PreFace study is the first that has examined this association during
the first 12 months of adjuvant letrozole therapy. The level of CAM
use, at about 64.5% of the patients included, lies within the range of
what other analyses have reported [35]. Prevalence rates of CAM
use in breast cancer range from 63% to 83% [33,36,37].It needs to be investigated why patients who use CAM have
higher pain levels before the beginning of AI therapy as well as in
the course of the first treatment year. It might be hypothesized that
CAM users a priori have a greater susceptibility to pain, leading to a
larger percentage of CAM users in this patient population. CAM
users might also perhaps have more precise self-perception and be
more attentive to themselves and their body d so that these pa-
tients might be more attracted to integrative therapy methods in
case of myalgia/limb pain and arthralgia than patients without
pain. CAM users might therefore be patients with a specific char-
acter profile and personality traits who are liable to use CAM in
order to improve their quality of life. There are few data in the
literature on this aspect [38e43]. A large study including 3032
adults aged 25e74 in the USA found that CAM use was associated
with the diagnosis of mental disorders, such as major depression
and panic disorders [38]. A cohort study have shown a positive
association between alternative medicine and depression, fear of
Fig. 3. Arthralgia during the course of treatment. Solid curves show (a) mean pain values and (b) mean pain value changes since begin of aromatase inhibitor (AI) treatment. The
corresponding 95% confidence intervals are indicated by the lines with long dashes. CAM, complementary and alternative medicine.
C.C. Hack et al. / The Breast 50 (2020) 11e1816recurrence of cancer, mental distress, sexual dissatisfaction and
physical complaints [44]. These aspects all show that there is a need
for further research on this topic.
We could show that CAM use before AI therapy does not prevent
the incidence of AIMSS or improve the time-related development of
pain. Since the expectations of many CAM users that CAM might
reduce AIMSS remain unsatisfied, these women are at a higher risk
of non-compliance, therapy discontinuation and an associated
worse prognosis [45]. In a large retrospective observational study
patients with CAM use were more likely to refuse conventional
cancer treatment and had therefore a higher mortality risk [46]. In
view of that, patients using CAM should receive an additional ed-
ucation and the offer of other therapeutic support. As the same
standards of antihormonal therapy applies in Western industrial-
ized countries in general and the use of CAM is also common there,
the results of this study can be transferred to other industrialized
countries.
This study has several strengths and limitations. One strength is
the large number of patients included and recruited throughout
Germany. However, a substantial number of patients were excluded
for various reasons; approximately 32.8% of the patients were
excluded by the study team for several reasons. This may have led
to a selection bias. In addition, usage of analgesics was not included
in the analysis, and this could have influenced the pain scores.
Furthermore, while our patients were enrolled between 2009 and
2010, CAM use gained even more attention in the following years.
Searching for the terms “complementary and alternative medicine”
and “breast cancer” in PubMed, it delivers results from 1998 to
2019, with themajority of them being published in the past decade.
Therefore, considering the gap of ten years between our patient
recruitment and publication of results, a similar investigation today
may lead to other results due the increased popularity of CAM over
the last years. But this remains a hypothesis. A benefit is that the
diary was able to collect detailed and extensive information from
the patients over the study period. The use of a diary to obtain a
history of patient information is unique in medical research. Pain
cards and pain scales were used as validated instruments to record
pain locations and scores.5. Conclusion
In conclusion, this study demonstrated that the intensity of pain
was generally greater in the CAM group than in the non-CAM
group. However, changes in pain increase appeared to be similar
in the two patient groups within the first 12months. Thus, CAM use
does not prevent or improve the development of AIMSS. But a large
proportion of postmenopausal breast cancer patients (64%) make
use of ongoing CAM after a diagnosis of breast cancer. Therefore,
because of the risk of non-compliance and treatment discontinu-
ation due to the development of higher pain levels, special atten-
tion must be paid to patient education and aftercare in these
patients.
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